UP!

News

Celldex Therapeutics, Inc. 2.79% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-24 Future report Set alerts
Q3 2020 2020-11-10 Future report Set alerts
Q2 2020 2020-08-06 -0.50 -0.50
Q1 2020 2020-05-06 -0.73 -0.73
Q4 2019 2020-03-26 -0.64 -0.64
Q3 2019 2019-11-12 -0.75 -0.75
Q2 2019 2019-08-07 -0.84 -0.84
Q1 2019 2019-05-07 -1.40 -1.40
Q4 2018 2019-03-07 -0.81 -0.75
Q3 2018 2018-11-07 -0.60 -0.60

Ratings

2016-06-07 Reiterated Rating Cowen and Company Outperform $12.00
2016-05-06 Reiterated Rating Wedbush Neutral $3.00
2016-05-06 Reiterated Rating Jefferies Group Hold $4.00
2016-04-19 Reiterated Rating Cowen and Company Outperform $12.00
2016-04-19 Reiterated Rating Roth Capital Buy $7.00
2016-03-08 Reiterated Rating Roth Capital Buy
2016-03-08 Reiterated Rating Brean Capital Buy $24.00
2016-03-08 Lower Price Target HC Wainwright Buy $25.00 to $6.00
2016-03-08 Reiterated Rating Cowen and Company Outperform $28.00 to $12.00
2016-03-07 Downgrade Leerink Partner Outperform to Market Perform
2016-03-07 Downgrade Jefferies Group Buy to Hold $31.00 to $4.00
2016-03-07 Downgrade Leerink Swann Outperform to Market Perform $30.00 to $4.00
2016-03-07 Downgrade Wedbush Outperform to Neutral $4.00
2016-03-07 Downgrade Oppenheimer Outperform to Market Perform
2016-03-07 Downgrade Guggenheim Buy to Neutral
2016-03-07 Downgrade Oppenheimer Holdings Inc. Outperform to Market Perform
2016-03-01 Initiated Coverage HC Wainwright Buy $25.00
2016-02-26 Lower Price Target Cantor Fitzgerald Buy $31.00 to $25.00
2016-02-25 Reiterated Rating Wedbush Outperform $24.00
2015-11-24 Initiated Coverage Roth Capital $39.00
2015-11-09 Reiterated Rating Brean Capital Buy $31.00
2015-09-15 Reiterated Rating Cowen and Company Buy $28.00
2015-08-27 Reiterated Rating Roth Capital Buy
2015-08-14 Reiterated Rating Leerink Swann Outperform $45.00
2015-08-11 Reiterated Rating Cowen and Company Outperform $34.00 to $28.00
2015-08-11 Lower Price Target Cantor Fitzgerald Buy $38.00 to $31.00
2015-08-11 Lower Price Target Oppenheimer Outperform $45.00 to $42.00
2015-08-11 Lower Price Target Brean Capital Buy $35.00 to $31.00
2015-08-11 Lower Price Target Roth Capital Buy $43.00 to $39.00
2015-06-30 Reiterated Rating Oppenheimer Buy $45.00
2015-06-30 Reiterated Rating Roth Capital Buy $43.00
2015-06-02 Reiterated Rating Brean Capital Buy $35.00
2015-06-02 Reiterated Rating Cantor Fitzgerald Buy $38.00
2015-06-01 Reiterated Rating WBB Securities Buy $30.00 to $40.00
2015-06-01 Set Price Target Cowen and Company Buy $33.00 to $34.00
2015-05-05 Reiterated Rating Cantor Fitzgerald Buy $38.00
2015-03-18 Reiterated Rating Jefferies Group Buy $24.00 to $36.00
2015-03-11 Boost Price Target Cantor Fitzgerald Buy $33.00 to $38.00
2015-02-23 Set Price Target Cowen and Company Buy $26.00
2014-12-19 Set Price Target Cantor Fitzgerald Buy $33.00
2014-11-17 Reiterated ROTH Capital Buy $40 to $43
2014-11-17 Reiterated Rating Oppenheimer $36.00
2014-11-17 Boost Price Target Roth Capital Buy $40.00 to $43.00
2014-09-26 Initiated Coverage Cowen and Company Outperform $22.00
2014-04-28 Upgrade Ned Davis Research Sell to Neutral
2014-03-04 Boost Price Target Jefferies Group Buy $29.00 to $31.00
2014-03-04 Reiterated Rating Cantor Fitzgerald Buy $39.00 to $33.00
2014-03-04 Lower Price Target Oppenheimer Outperform $40.00 to $36.00
2013-11-07 Reiterated Rating Brean Capital Buy
2013-10-22 Reiterated Rating Oppenheimer Buy $40.00
2013-10-22 Reiterated Rating Cantor Fitzgerald Buy $39.00
2013-10-22 Boost Price Target Roth Capital Buy $34.00 to $40.00
2013-10-07 Initiated Coverage Ned Davis Research Neutral
2013-10-02 Reiterated Rating Cantor Fitzgerald Buy $39.00
2013-10-02 Boost Price Target Oppenheimer $40.00
2013-09-24 Boost Price Target Guggenheim Buy $26.00 to $34.00
2013-09-24 Boost Price Target Cantor Fitzgerald Buy $39.00
2013-09-23 Boost Price Target Leerink Swann Outperform $28.00 to $45.00
2013-09-17 Reiterated Rating Wedbush Buy $35.00
2013-09-17 Boost Price Target Jefferies Group Buy $25.00 to $29.00
2013-07-08 Reiterated Cantor Fitzgerald Buy $16 to $24
2013-03-08 Reiterated Cantor Fitzgerald Buy $13 to $16
2013-01-10 Reiterated Cantor Fitzgerald Buy $9 to $13
2012-09-14 Reiterated Cantor Fitzgerald Buy $7 to $9
2012-04-04 Initiated Cantor Fitzgerald Buy $7
2011-11-02 Reiterated Brean Murray Buy $16 to $14
2010-05-05 Reiterated WBB Securities Strong Buy $10 to $15
2009-09-29 Initiated WBB Securities Strong Buy $10
2008-12-19 Reiterated Brean Murray Buy $19 to $16
2008-10-24 Initiated Merriman Curhan Ford Buy
2016-06-07 Reiterated Rating Cowen and Company Outperform $12.00
2016-05-06 Reiterated Rating Wedbush Neutral $3.00
2016-05-06 Reiterated Rating Jefferies Group Hold $4.00
2016-04-19 Reiterated Rating Cowen and Company Outperform $12.00
2016-04-19 Reiterated Rating Roth Capital Buy $7.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
MEDAREX INC 3.31%  (2960848) CLDX /
van den Broek Richard 0.26%  (233500) CLDX / PCYC / RGDX /
McMahon Gerald PhD 0.22%  (200549) CLDX / OXGN /
SHANNON TIMOTHY M 0.09%  (83212) CLDX /
CATLIN AVERY W Sr. VP & CFO 0.08%  (73586) CLDX /
ELLBERGER LARRY 0.08%  (73500) CLDX /
Marucci Anthony S President & CEO 0.06%  (50028) CLDX /
PENNER HARRY JR 0.05%  (41916) CLDX /
LIPTON KAREN SHOOS 0.05%  (41833) CLDX /
CONRAD HERBERT J 0.04%  (38500) CLDX / TKMR /
Elston George 0.03%  (28500) CBRX / CLDX /
MARINO JAMES J 0.03%  (25997) CLDX / ONTX /
KELER TIBOR Sr. VP & CSO 0.02%  (15868) CLDX /
Brownlie Keith L 0.01%  (10000) CGIX / CLDX / IMNP / RXII / SNGX /
Newbold Ronald C Sr. VP, Business Dev. 0.01%  (5868) CLDX /
SCHALLER CHARLES R 0.01%  (5000) CLDX /

Comments